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Abstract
Background: Pulmonary sarcoidosis involves an intense leukocyte infiltration of the lung with the formation of
non-necrotizing granulomas. CC chemokines (chemokine (C-C motif) ligand 2 (CCL2)-CCL5) are chemoattractants of
mononuclear cells and act through seven transmembrane G-coupled receptors. Previous studies have
demonstrated conflicting results with regard to the associations of these chemokines with sarcoidosis. In an effort
to clarify previous discrepancies, we performed the largest observational study to date of CC chemokines in
bronchoalveolar lavage fluid (BALF) from patients with pulmonary sarcoidosis.
Results: BALF chemokine levels from 72 patients affected by pulmonary sarcoidosis were analyzed by enzyme-
linked immunosorbent assay (ELISA) and compared to 8 healthy volunteers. BALF CCL3 and CCL4 levels from
pulmonary sarcoidosis patients were not increased compared to controls. However, CCL2 and CCL5 levels were
elevated, and subgroup analysis showed higher levels of both chemokines in all stages of pulmonary sarcoidosis.
CCL2, CCL5, CC chemokine receptor type 1 (CCR1), CCR2 and CCR3 were expressed from mononuclear cells
forming the lung granulomas, while CCR5 was only found on mast cells.
Conclusions: These data suggest that CCL2 and CCL5 are important mediators in recruiting CCR1, CCR2, and CCR3
expressing mononuclear cells as well as CCR5-expressing mast cells during all stages of pulmonary sarcoidosis.
Background
Sarcoidosis is an immune-mediated multisystem disease
of unknown etiology [1]. It involves the lung in over 90%
of the cases and is a common cause of interstitial lung
disease with some patients eventually requiring lung
transplantation [1-3]. Pulmonary sarcoidosis is diagnosed
via compatible clinicoradiographic findings with histologi-
cal evidence of non-necrotizing granulomas in the
absence of infection or other causative etiologies that can
also cause pulmonary granulomas [4]. Pathologically, sar-
coidosis is characterized by an initial T cell alveolitis that
is dominated by a type 1 immune response environment
[5-7]. This response leads to the recruitment and activa-
tion of mononuclear cells that eventually evolves into
non-necrotizing granulomas [4,5]. Importantly, at some
point between the transition from stage I to III pulmon-
ary sarcoidosis there may be a conversion from a local
inflammatory type 1 response to a more fibroproliferative
type 2 response where inflammation gives way to pul-
monary fibroplasia.
Chemokines recruit mononuclear cell subpopulations
via specific receptors [8]. Different types of chemokines
have been implicated in early and late stages of sarcoidosis
[9]. For instance, we and others have found that the type 1
immune response interferon inducible CXC chemokines
(CXCL9, CXCL10, and CXCL11) are associated with the
early stages (stage I and II) but not late stage III pulmon-
ary sarcoidosis [10-12]. Thus, it is plausible that alternative
chemokines may be involved in the transition from early
inflammatory stages (for example, type 1 immune
responses) to late profibrotic stages (for example, type 2
immune responses) of pulmonary sarcoidosis. The CC
chemokine subfamily themselves (for example, chemokine
(C-C motif) ligand 5 (CCL5; also known as ‘regulated
upon activation, normal t cell expressed, and secreted’
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(MIP)-1a), CCL4 (MIP-1b), CCL2 (monocyte chemotactic
protein-1 (MCP-1))) have been shown to straddle the con-
tinuum from type 1 to type 2 immune responses making
these chemokines likely candidates to be involved in the
overall pathogeneses of pulmonary sarcoidosis [13]. There
are conflicting results with regards to CC chemokines and
their association with pulmonary sarcoidosis [14-22]. This
study was designed to determine whether there are aug-
mented levels of CC chemokines in bronchoalveolar lavage
fluid (BALF) from patients with the clinical/pathological
diagnosis of pulmonary sarcoidosis and to resolve the cur-
rent discrepancies within the literature. Moreover, this
study aims to elucidate the cellular sources of specific CC
chemokines and their receptors during the pathogenesis of
pulmonary sarcoidosis.
Results
Patient characteristics
We identified 72 patients affected with different stages of
pulmonary sarcoidosis as well as 8 healthy volunteers
(Table 1). More specifically, there were 27 (38%) patients
with stage I disease, 36 (50%) with stage II disease and 9
(12%) with stage III disease (Table 1). Using the definition
of active pulmonary lymphocytic alveolitis as a bronchoal-
veolar lavage (BAL) lymphocyte count greater than 30 ×
10
3 lymphocytes/ml, there were 27 (37%) patients with and
45 (63%) patients without an active alveolitis (Table 1). In
all, 8 (11%) patients were on and 64 (89%) patients were off
empiric immunosuppressive treatment at the time of their
diagnostic bronchoscopy (Table 1). Additional pulmonary
sarcoidosis patient characteristics such as age, sex, race and
pulmonary function testing are outlined in Tables 1 and 2.
Eight healthy volunteers without pulmonary symptoms,
with normal chest radiographs and no relevant medical
history underwent a bronchoscopy and were deemed the
healthy control group.
CCL3 and CCL4 protein levels in BALF are not elevated in
pulmonary sarcoidosis
BALF CCL3 and CCL4 protein levels measured by
enzyme-linked immunosorbe n ta s s a y( E L I S A )w e r en o t
significantly elevated in patients with sarcoidosis (n =
7 2 )c o m p a r e dw i t hn o r m a lh e a l t h yc o n t r o l s( n=8 )
(Figures 1a and 2a). There were no significant differ-
ences in BALF CCL3 and CCL4 protein levels compar-
ing healthy controls to patients with stages I, II or III
sarcoidosis (Figures 1b and 2b). There were no signifi-
cant differences in BALF CCL3 and CCL4 protein levels
in a three-group comparison across the different stages
of sarcoidosis (stage I (n = 27), stage II (n = 36) and
stage III (n = 9)) (Figures 1b and 2b). The presence of a
lymphocytic alveolitis (n = 27) had no impact on CCL3
and CCL4 levels (Figures 1c and 2c). Furthermore,
empiric immunosuppressive therapy (n = 8) at the time
of diagnostic bronchoscopy did not affect CCL3 and
CCL4 protein levels (Figures 1d and 2d).
CCL5 protein levels in BALF are elevated in pulmonary
sarcoidosis and the cellular sources are mononuclear cells
that form the non-necrotizing granulomas
The BALF protein levels of CCL5 were significantly
higher in sarcoidosis patients as compared to controls
(Figure 3a). Subgroup analysis demonstrated that CCL5
levels were significantly higher in all stages (stage I, II,
III), as compared to healthy controls (Figure 3b). There
were no differences between patients with and without
alveolitis (Figure 3c). Similarly, there were no differences
between those patients who were receiving or not
receiving empiric immunosuppressive therapy targeted
at pulmonary sarcoidosis (Figure 3d).
Using immunohistochemical techniques we determined
the cellular sources of CCL5 during all stages of pulmon-
ary sarcoidosis, those with and without alveolitis, and
those on or off empiric therapy. We found that the main
cellular sources of CCL5 were epithelioid histiocytes, mul-
tinucleated giant cells, surrounding alveolar macrophages
and a minor component was other inflammatory mono-
nuclear cells that formed the non-necrotizing granulomas
(Figure 3e). This pattern was consistent in all stages of sar-
coidosis irrespective of alveolitis or concurrent immuno-
suppressive therapy, with the exception of stage III
pulmonary sarcoidosis in which there were no cases that
were on therapy at the time of diagnostic bronchoscopy.
Table 1 Characteristics of the pulmonary sarcoidosis patients
Pulmonary
Sarcoidosis Stages
Patients
(n)
Age,
years
Sex Race Lymphocytic
Alveolitis
Immuno-suppressive
Therapy
Males Females African-
Americans
White Others
I 27 39 ± 8 17(63) 10(37) 9(34) 12(44) 6(22) 13(48) 5(18)
II 36 39 ± 11 15(42) 21(58) 12(34) 20(55) 4(11) 12(33) 3(8)
III 9 54 ± 10 2(22) 7(78) 3(33) 5(55) 1(12) 2(22) 0(0)
Data are presented as mean ± SD or n (%), unless otherwise stated.
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Page 2 of 12CCL2 protein levels in BALF are elevated in pulmonary
sarcoidosis and the cellular sources are mononuclear cells
that form the non-necrotizing granulomas
The BALF protein levels of CCL2 were significantly
higher in sarcoidosis patients as compared to controls
( F i g u r e4 a ) .S u b g r o u pa n a l y s i sd e m o n s t r a t e dt h a tB A L F
protein levels of CCL2 were significantly higher in all
stages, as compared to controls (Figure 4b). There were
no significant differences between patients with and
without alveolitis or between those patients who were
receiving or not receiving empiric immunosuppressive
therapy targeted at pulmonary sarcoidosis (Figure 4c,d).
Using immunohistochemical techniques we deter-
mined the cellular sources of CCL2 during all stages of
pulmonary sarcoidosis including those with and without
alveolitis and those on or off empiric therapy. We found
that the main cellular source of CCL2 was epithelioid
histiocytes, multinucleated giant cells, surrounding
alveolar macrophages with a minor component being
other infiltrating mononuclear cells that formed the
Table 2 Pulmonary function test results of the pulmonary sarcoidosis patients
Pulmonary Sarcoidosis
Stages
FEV1 L FEV1%
predicted
FVC L FVC %
predicted
TLC L TLC %
predicted
DLCO ml min-1
mHg-1
DLCO %
predicted
I 3.1 ± 0.9 87.6 ± 21.2 3.8 ± 1.3 85.6 ± 21.3 5.9 ± 0.9 84.4 ± 18.9 27.1 ± 6.9 90.6 ± 17.2
II 2.9 ± 1.0 82.8 ± 21.4 3.7 ± 1.1 83.5 ± 18.9 5.5 ± 1.1 83.8 ± 37.8 23.2 ± 7.4 70.2 ± 16.9
III 1.5 ± 0.6 61.7 ± 25.0 2.4 ± 1.1 73.7 ± 33.3 3.3 ± 0.0 71.0 ± 0.0 13.5 ± 2.1 61.0 ± 8.5
Data are presented as mean ± SD or n (%), unless otherwise stated. FEV1: forced expiratory volume in 1 sec; FVC: forced vital capacity; TLC: total lung capacity;
DLCO: diffusing capacity of the lung for carbon monoxide.
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Figure 1 Bronchoalveolar lavage fluid (BALF) protein levels of chemokine (C-C motif) ligand 3 (CCL3) from patients with sarcoidosis
were not elevated as compared to normal healthy controls. BALF protein levels of CCL3 by enzyme-linked immunosorbent assay (ELISA)
from (a) all sarcoidosis patients (n = 72) compared with normal healthy volunteers (n = 8), (b) different stages of sarcoidosis (stage I (n = 27),
stage II (n = 36) and stage III (n = 9)), (c) sarcoid patients with (n = 27) and without (n = 45) alveolitis, and (d) sarcoidosis patients with (n = 8)
and without (n = 64) empirical treatment at the time of diagnosis.
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Page 3 of 12non-necrotizing granulomas (Figure 4e). This pattern
was consistent in all stages of sarcoidosis irrespective of
alveolitis or concurrent immunosuppressive therapy,
with the exception of stage III pulmonary sarcoidosis in
which there were no cases that were on therapy at the
time of diagnostic bronchoscopy.
Cellular sources of CC chemokine receptor type 1 (CCR1),
CCR2, CCR3 and CCR5 during pulmonary sarcoidosis
The mononuclear cell receptor(s) for CCL2 is CCR2 and
for CCL5 are CCR1, CCR3 and CCR5. We found that at
all stages of pulmonary sarcoidosis including those with or
without alveolitis and those on or off immunosuppressive
therapy main cellular sources of CCR1, CCR2, and CCR3
were epithelioid histiocytes, multinucleated giant cells and
other infiltrating mononuclear cells that formed the non-
necrotizing granulomas (Figure 5). However, when we
evaluated the cells expressing CCR5 we found the only
cell type expressing this chemokine receptor were mast
cells infiltrating the non-necrotizing granulomas (Figure
6i-k, m, n). This finding was consistent irrespective of sar-
coid stage, alveolitis, or concurrent immunosuppressive
therapy.
Discussion
The CC chemokine cascades involved in the recruitment
of mononuclear cells that eventually leads to the forma-
tion of non-necrotizing granulomas during pulmonary
sarcoidosis has not been fully elucidated. While there
have been multiple studies determining if alterations in
CC chemokines are associated with sarcoidosis, collec-
tively there are many inconsistencies [14-22]. In an
effort to clarify discrepancies between these studies, we
performed the largest observational study involving
BALF CC chemokines (CCL2, CCL3, CCL4, and CCL5)
during the pathogenesis of pulmonary sarcoidosis.
CCL3 and CCL4 are CC chemokines that are known
to recruit mononuclear cells with CCL3 having a
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Figure 2 Bronchoalveolar lavage fluid (BALF) protein levels of chemokine (C-C motif) ligand 4 (CCL4) from patients with sarcoidosis
were not elevated as compared to normal healthy controls. BALF protein levels of CCL4 by enzyme-linked immunosorbent assay (ELISA)
from (a) all sarcoidosis patients (n = 72) compared with normal healthy volunteers (n = 8), (b) different stages of sarcoidosis (stage I (n = 27),
stage II (n = 36) and stage III (n = 9)), (c) sarcoid patients with (n = 27) and without (n = 45) alveolitis, and (d) sarcoidosis patients with (n = 8)
and without (n = 64) empirical treatment at the time of diagnosis.
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Figure 3 Bronchoalveolar lavage fluid (BALF) protein levels of chemokine (C-C motif) ligand 5 (CCL5) from patients with sarcoidosis
were elevated as compared to normal healthy controls. BALF protein levels of CCL5 by enzyme-linked immunosorbent assay (ELISA) from
(a) all sarcoidosis patients (n = 72) compared with normal healthy volunteers (n = 8), (b) different stages of sarcoidosis (stage I (n = 27), stage II
(n = 36) and stage III (n = 9)), (c) sarcoid patients with (n = 27) and without (n = 45) alveolitis, and (d) sarcoidosis patients with (n = 8) and
without (n = 64) empirical treatment at the time of diagnosis. *P = 0.002 for sarcoid versus normal; **P < 0.04 for stage I, II, and III verses normal;
***P < 0.04 for with or without alveolitis versus normal; ****P < 0.04 for with or without treatment verses normal. Representative
immunohistochemistry for CCL5 (e-g) and isotype control antibody (h) on lung biopsy tissue from stages II pulmonary sarcoidosis without
alveolitis and on empiric therapy. Representative immunohistochemistry for CCL5 (i-k) and isotype control antibody (l) on lung biopsy tissue
from stages III pulmonary sarcoidosis without alveolitis or empiric therapy. CCL5 protein expression was found in epithelioid histiocytes and
multinucleated giant cells forming non-necrotizing granulomas, as well as from surrounding alveolar macrophages and other infiltrating
mononuclear cells. Panels were photographed at 50 × (e, i, h, l), 100 × (f, j), and 200 × (g, k) original magnification.
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Figure 4 Bronchoalveolar lavage fluid (BALF) protein levels of chemokine (C-C motif) ligand 2 (CCL2) from patients with sarcoidosis
were elevated as compared to normal healthy controls. BALF protein levels of CCL2 by enzyme-linked immunosorbent assay (ELISA) from
(a) all sarcoidosis patients (n = 72) compared with normal healthy volunteers (n = 8), (b) different stages of sarcoidosis (stage I (n = 27), stage II
(n = 36) and stage III (n = 9)), (c) sarcoid patients with (n = 27) and without (n = 45) alveolitis, and (d) sarcoidosis patients with (n = 8) and
without (n = 64) empirical treatment at the time of diagnosis. *P = 0.001 for sarcoid versus normal; **P < 0.004 for stage I, II, and III verses
normal; ***P < 0.004 for with or without alveolitis versus normal; ****P < 0.01 for with or without treatment verses normal. Representative
immunohistochemistry for (e) CCL2 and (f) isotype control antibody on lung biopsy tissue from stage I pulmonary sarcoidosis without alveolitis
and on empiric therapy. CCL2 protein expression was found in epithelioid histiocytes and multinucleated giant cells forming non-necrotizing
granulomas, as well as from surrounding alveolar macrophages and other infiltrating mononuclear cells. Panels were photographed at 50 ×
original magnification.
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Page 6 of 12preferential activity for CD8 T cells and CCL4 for CD4 T
cells [23]. Two studies have found associations between
elevated levels of CCL3 or CCL4 protein/cell pellet
mRNA expression from BALF in patients with sarcoido-
sis [14,17]. Specifically, Oshima and associates using a
cohort of pulmonary sarcoidosis patients (n = 17) found
that the expression of CCL3 from BALF cell pellets was
elevated as compared to other interstitial lung diseases (n
= 10) [17]. Likewise, Capelli and colleagues demonstrated
higher BALF CCL3 and CCL4 protein levels from sarcoi-
dosis patients (n = 30) as compared to healthy controls
(n = 18) [14]. In the present study, we analyzed the lar-
gest cohort of pulmonary sarcoidosis patients for CCL3
and CCL4 (n = 72) and did not find alterations in protein
levels compared to healthy controls. We also performed
exploratory subgroup analyses and could not demon-
strate differences among different stages of sarcoidosis,
those cases with or without alveolitis, or those cases on
or off empiric immunosuppressive therapy at the time of
diagnosis. These finding are corroborated by a smaller
sarcoidosis cohort [22] and suggest that CCL3 and CCL4
are unlikely to have a significant role in the pathogenesis
of pulmonary sarcoidosis.
Differences in BALF CCL5 protein levels were not
found in a cohort of sarcoidosis patients (n = 22) as
compared to healthy volunteers [22]. Similar results
were found in a larger study of sarcoidosis patients (n =
60) [18]. Conversely, we found an association between
elevated BALF protein levels of CCL5 and pulmonary
sarcoidosis. Interestingly, the stage of pulmonary sarcoi-
dosis, alveolitis, and immunosuppressive therapy at the
time of pulmonary sarcoidosis diagnosis did not signifi-
cantly affect the levels of CCL5. To confirm these
results we evaluated the sources of CCL5 from lung
biopsy tissue from all stages of pulmonary sarcoidosis,
those with or without alveolitis and those on or off
empiric immunosuppressive therapy. In all cases CCL5
was being expressed from epithelioid histocytes, multi-
nucleated giant cells, surrounding alveolar macrophages
and other infiltrating mononuclear cells creating the sar-
coid lung granulomas. These immunohistochemistry
results explain the elevated level of CCL5 found in
Figure 5 Immunohistochemistry for CC chemokine receptor type 2 (CCR2) on lung biopsy tissues. Representative immunohistochemistry
for CCR2 (a-c) and isotype control antibody (d) on lung biopsy tissue from stages II pulmonary sarcoidosis without alveolitis and on empiric
therapy. CCR2 protein expression was found in epithelioid histiocytes and multinucleated giant cells forming non-necrotizing granulomas, as well
as from surrounding alveolar macrophages and other infiltrating mononuclear cells. Panels were photographed at 50 × (a, d), 100 × (b), and
200 × (c) original magnification.
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Page 7 of 12patients with or without alveolitis and those on or off
therapy for pulmonary sarcoidosis as all the non-necro-
tizing lung granulomas were producing CCL5 (for
example, despite therapy or no alveolitis). Furthermore,
we feel the reasons for the differences between our
results and those from the other large study [18] has to
do with the differences in study design. More specifi-
cally, we only included ‘pulmonary’ sarcoidosis patients
(appropriate radiographic changes and lung biopsies
with non-necrotizing granulomas) whereas the other
study included BALF from patients with stage 0 sarcoi-
dosis (no radiographic feature and no evidence of non-
Figure 6 Immunohistochemistry for CC chemokine receptor type 1 (CCR1), CCR3 and CCR5 on lung biopsy tissues.R e p r e s e n t a t i v e
immunohistochemistry for CCR1 (a-d), CCR3 (e-g), CCR5 (i-k, m), mast cells via tryptase (n) and appropriate isotype control antibodies (d, h, l)
on lung biopsy tissue from stage II pulmonary sarcoidosis without alveolitis and on empiric therapy. CCR1 and CCR3 protein expression was
found in epithelioid histiocytes and multinucleated giant cells forming non-necrotizing granulomas, as well as from surrounding alveolar
macrophages and other infiltrating mononuclear cells. CCR5 protein expression was found in mast cells (i-k, m-n). The red arrows indicate mast
cells (n) are expressing CCR5 (m). Panels were photographed at 50 × (a, d, e, h, i, l), 100 × (b, f, j, m, n) and 200 × (c, g, k) original magnification.
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BALF protein level of CCL5 in those patients with stage
0 sarcoidosis would expectantly have no alterations as
there are no granulomatous lesions present to produce
CCL5. Moreover, our results are supported by other
smaller investigations that have also found BALF pro-
teins levels of CCL5 to be associated with pulmonary
sarcoidosis [16,19].
CCL5 chemotactic activity for mononuclear cells
involves three CC chemokine receptors (CCR1, CCR3,
and CCR5) [8,24]. We determined what the cellular
sources of these receptors were in pulmonary sarcoido-
sis. We found that epithelioid histocytes, macrophages
and infiltrating lymphocytes that form the pulmonary
sarcoid non-necrotizing granuloma were all expressing
CCR1 and CCR3. Surprisingly, CCR5 was only found on
non-necrotizing granuloma infiltrating mast cells. This
suggests that CCL5 involvement in sarcoid granuloma-
tous formation is important for mononuclear phagocyte,
lymphocyte as well as mast cell recruitment. There are
reports suggesting the involvement of mast cells in pul-
monary sarcoidosis [25-27] as well as other fibrotic lung
disorders [28-30]. Collectively, with our study demon-
strating that CCL5 is altered in all stages of sarcoidosis
it is conceivable that CCL5 via its recruitment effect on
mononuclear cells, including mast cells, could be a key
chemokine that is involved in the continuum of intense
inflammatory injury during early stages to the more
chronic inflammatory/fibrosis during late stages of pul-
monary sarcoidosis.
Multiple studies involving either BALF protein levels
or cell pellet mRNA expression of CCL2 have found no
significant association between CCL2 and sarcoidosis
[16,17]. To the contrary, our results demonstrated
marked elevations of BALF protein levels of CCL2 in
patients with pulmonary sarcoidosis. The levels of CCL2
were elevated in every stage of pulmonary sarcoidosis, in
those with or without alveolitis and in those on or off
immunosuppressive therapy. These findings were sub-
stantiated by immunohistochemical studies demonstrat-
ing CCL2 expression by epithelioid histiocytes,
multinucleated giant cells within granulomas, as well as
surrounding alveolar macrophages in all stages of sarcoi-
dosis. These results are supported by smaller studies
demonstrating increased protein levels or mRNA
expression of CCL2 in BALF from pulmonary sarcoido-
sis patients [15,18,20,21]. Interestingly, we found that
CCR2, the only receptor for CCL2, was expressed by the
same cell types that express CCL2. Previous investiga-
tions found that CCL2 can augment cellular expression
of transforming growth factor b and lead to fibroplasia
[31]. Collectively, these results indicate that the CCR2/
CCL2 biological axis may act in an autocrine and para-
crine manner. Plausibly, this CCR2/CCL2 axis can
recruit mononuclear cells that form and expand the
granulomatous disease during early inflammatory stages
of pulmonary sarcoidosis. However, persistent expres-
sion of CCL2 interacting with CCR2 can lead to the
fibroplasia of late stages of pulmonary sarcoidosis.
Conflicting results have also been described when
evaluating CCR2 polymorphisms associated with sarcoi-
dosis [32-35]. The differences between CCR2 poly-
morphism investigations in sarcoidosis may be explained
by linkage disequilibrium between CCR2 gene variants
and polymorphisms in a neighboring sarcoidosis sus-
ceptibility gene. Collectively, these polymorphisms stu-
dies [32-35] combined with the results of our study
would suggest that polymorphisms that cause CCR2
dysfunction may lead to a sarcoidosis phenotype that is
less severe. However, other chemokine axes (for exam-
ple, CCL5/receptors and interferon inducible ELR-CXC
chemokines) may also have to be dysfunctional for these
sarcoidosis patients to have significantly less severe
disease.
Conclusions
Overall this study suggests that CCL2 and CCL5 may
be interacting with mononuclear cells expressing speci-
fic CC chemokines receptors (CCL2 ® CCR2, CCL5
® CCR1, CCR3, and CCR5) and are important biolo-
gically in the formation of pulmonary sarcoidosis gran-
ulomas. Furthermore, unlike other chemokines (for
example, interferon inducible CXC chemokines), that
were only found to be elevated during early stage of
pulmonary sarcoidosis [10], CCL2 and CCL5 are ele-
vated in all stages of pulmonary sarcoidosis indicating
a possible function for the continuum of early inflam-
matory to late fibrotic sarcoidosis. Additionally, our
novel finding that CCR5 is expressed solely on the
mast cells adds credence to the notion that mast cells
may have some capacity to perpetuate sarcoid granulo-
mas. Furthermore, based on our results as well as
those from other investigators we think that CCL3 and
CCL4 do not have a substantial role in the pathogen-
esis of pulmonary sarcoidosis. Only future prospective
studies will be able to determine if the levels of CCL2
and CCL5 are predictive of outcomes and if the com-
bined inhibition of these receptor(s)/ligand(s) interac-
tions may lead to an inhibition of progression or even
reversal of this lung disease.
Methods
Study design and patient population
With Institutional Review Board (IRB) approval and
informed written consent, we prospectively enrolled all
patients undergoing bronchoscopy for interstitial lung
disease from June 1993 to December 2003. Patients
were eligible for enrollment if they were suspected of
Palchevskiy et al. Fibrogenesis & Tissue Repair 2011, 4:10
http://www.fibrogenesis.com/content/4/1/10
Page 9 of 12having an interstitial lung disease. For this specific study
we retrospectively identified 72 patients who had an
initial de novo confirmed clinical/pathological diagnosis
of pulmonary sarcoidosis. All patients underwent a
bronchoscopy with transbronchial lung biopsy with or
without a video-assisted thoracoscopic (VATS) biopsy,
open lung biopsy or mediastinoscopy. The diagnosis of
sarcoidosis was made if the patient’s lung biopsy (trans-
bronchial biopsy (n = 59, 82%) and surgical biopsy (n =
13, 18%)) showed discrete, well formed, non-necrotizing
granulomas without evidence of infection or inorganic
material to account for the pulmonary granulomatous
reaction. Throughout the ent i r es t u d yw ee x c l u d e da n y
BAL performed at a time when infection and/or coloni-
zation was diagnosed via the following criteria: BALF or
lung biopsy positive Gram stain or culture for bacteria,
acid-fast bacillus, cytomegalovirus, respiratory viruses,
Pneumocystis jiroveci or other fungal organisms. Addi-
tionally, patients with positive histoplasmosis serum ser-
ology or urine antigen or positive coccidioidimycoses
serum serology were also excluded.
All patients with sarcoidosis were staged retrospec-
tively using a modification of the system outlined by the
American Thoracic Society (ATS)/European Respiratory
Society (ERS)/World Association of Sarcoidosis and
Other Granulomatous Disorders joint statement as pre-
viously described [36,37]. Criteria were as follows. Stage
I: bilateral hilar lymphadenopathy without pulmonary
infiltrates; stage II: bilateral hilar lymphadenopathy with
pulmonary infiltrates; and stage III: pulmonary infiltrates
and/or fibrosis in the absence of hilar lymphadenopathy
[36,37]. In addition, we also retrospectively characterized
these patients with or without an active pulmonary lym-
phocytic alveolitis defined by a BAL lymphocyte count
greater than 30 × 10
3 lymphocytes/ml as previously
described [10,38]. Furthermore, we identified eight sar-
coid patients being treated with empiric methylpredniso-
lone therapy for symptoms of arthralgia at the time of
their diagnostic bronchoscopy. BALF was also obtained
from eight healthy control patients with no relevant
medical history, pulmonary symptoms or abnormal
radiographical findings.
BALF collection and process
Bronchoalveolar lavage was performed in both pul-
monary sarcoidosis patients and controls using stan-
dard techniques as previously described [10]. Briefly,
four 60 ml aliquots of sterile isotonic saline solutions
were instilled via a flexible bronchoscope wedged into
a subsegmental bronchus of a predetermined region of
interest based on radiographical findings, and lavage
fluid was aspirated back each time by low suction. The
pooled BALF was split equally into two samples. One
sample was dispatched for clinical microbiology/
cytology and the other sample was placed on ice and
transported to the research laboratory. The research
sample was filtered through sterile gauze and centri-
fuged (2000 rpm for 10 min) and the supernatant fluid
was immediately frozen at -70°C until thawed for che-
mokine analysis.
Immunoassay
The levels of CCL2, CCL3, CCL4, and CCL5 in BALF
were quantified via the manufacturer’sp r o t o c o lu s i n g
ELISA kits (R&D Systems; Minneapolis, MN, USA).
Immunohistochemistry for CC chemokines and their
receptors
Using immunohistochemical techniques we determined
the cellular sources of specific CC chemokines and their
appropriate receptors during all stages of pulmonary
sarcoidosis, those with and without alveolitis and those
on or off empiric therapy (stage I with alveolitis and off
therapy (n = 3), without alveolitis and on therapy (n =
3); stage II with alveolitis and off therapy (n = 3), with-
out alveolitis and on therapy (n = 3); and stage III with
alveolitis and off therapy (n = 2), without alveolitis and
off therapy (n = 2). Reagents for immunohistochemistry
included mouse anti-human CCL2, CCR1, and CCR5
monoclonal antibodies (Abs), goat anti-human CCL5
antibody, and rat anti-human CCR3 antibody, which
were purchased from R&D Systems. Rabbit monoclonal
anti-human CCR2 was purchased from Epitomics (Bur-
lingame, CA, USA). Mouse monoclonal anti-human to
mast cell tryptase was purchased from Abcam (Cam-
bridge, MA, USA). The expression of CCL2 and CCL5
and their receptors CCR1, CCR2, CCR3, CCR5 as well
as Tryptase was assessed by immunocytochemistry on
paraffin-embedded samples of lung tissue from sarcoido-
sis patients as previously described [10]. Briefly, staining
was performed using the VECTASTAIN ABC Standard
kits (Vector Laboratories, Inc., Burlingame, CA, USA).
After deparaffinization and antigen retrieval in sodium
citrate buffer (pH 6.0), endogenous perioxidase was
quenched with 3% hydrogen peroxide in PBS for
10 min. Non-specific binding was minimized by incuba-
tion in appropriate blocking serum for 30 min and
endogenous biotin was blocked with an avidin/biotin
blocking kit (Vector). Slides were then incubated over-
night with primary antibodies at 4°C. Specific labeling
was detected with a biotinylated specific secondary anti-
body and application of horseradish peroxidase-conju-
gated avidin-biotin followed by development with DAB
solution (Vector).
Statistical analysis
Demographic data as well as pulmonary function test
values were reported as mean ± standard error of the
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distributions; therefore, we transformed all data on log
10 for analysis. Levels of CCL2, CCL3, CCL4 and
CCL5 in BALF were compared between sarcoid
patients and controls using an unpaired t test. To eval-
uate differences by the stages of sarcoidosis, subgroup
analysis of variance (ANOVA) was performed and each
subgroup was compared with controls using an
unpaired t test. To assess the role the CC chemokines
in sarcoid patients with and without alveolitis, we cate-
gorized patients into two groups based upon BAL lym-
phocyte counts: alveolitis >30 × 10
3 cells/ml and
without alveolitis ≤30 × 10
3 cells/ml. We also per-
formed further subgroup analysis in patients who were
or were not on empiric immunosuppressive therapy at
t h et i m eo fp u l m o n a r ys a r c o i dosis diagnosis. Unpaired
t test was used to determine the differences in those
groups. Box and whisker plots were used to show the
distribution of data around the mean, median, 25th
and 75th interquartile ranges. All analysis was per-
formed with GraphPad Prism 5 statistical package
(GraphPad Software Inc, San Diego, CA, USA).
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